Company

Enzyre

Enzyre (founded in 2016) develops innovative diagnostic devices facilitating personalized medicine. Our mission is to improve quality of life of the patient whilst reducing healthcare costs by better diagnostics and disease management!

Enzyre believes that a prerequisite for personalized medicine is personalized diagnostics. We will enable personalized diagnostics by developing disposable biochips measuring, in one drop of blood, multiple parameters of specific interest to each patient group, with higher accuracy and at lower costs. Our initial biochip is tailored for hemophilia patients. Our second priority is a biochip for patients with blood coagulation disorders in an acute setting and thirdly we will focus on patients using anti-coagulants. In addition to blood coagulation our technology allows measurement of all types of enzymatic reactions, in a small volume with high accuracy and without the need of expensive equipment. For further inquiries, please contact us!

Enzyre

Transistorweg 5, Building M

6534 AT Nijmegen

Gelderland

+31 (0)6 28265405

waander@enzyre.com

Website

More companies in this area

Gatt Technologies

GATT Technologies is a privately owned, clinical-stage, medical device company.

Staten Biotechnology

Staten Biotechnology aims to develop novel and innovative strategies for the prevention of cardiovascular events, the largest unmet medical need in dyslipidemia.

SPL Medical

SPL Medical is strongly committed to improve MRI imaging to enable a much more precise, effective and patient friendly diagnosis of cancer metastasis.

QM Diagnostics

QM Diagnostics is an internationally operating, independent and innovative diagnostic microbiological laboratory.

We are specialized in health monitoring of small laboratory animals used for biomedical research.

Cardiacbooster

Developing the next generation of percutaneous left ventricular assist devices.

ATRO Medical

ATRO Medical is working hard on the transition to the clinic and the first implantation of a Trammpolin™ meniscus prosthesis in the patient is expected in 2020.

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!